| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-28 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -3.910 | -4.310 | -0.4000 | ||||
| REV | 334.620M | 178.844M | -155.776M |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Novavax (NASDAQ: NVAX) through any online brokerage.
Other companies in Novavax’s space includes: Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT) and Neurocrine Biosciences (NASDAQ:NBIX).
The latest price target for Novavax (NASDAQ: NVAX) was reported by Cowen & Co. on January 21, 2022. The analyst firm set a price target for 150.00 expecting NVAX to rise to within 12 months (a possible 80.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Novavax (NASDAQ: NVAX) is $82.92 last updated Fri Jan 28 2022 21:00:04 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Novavax.
Novavax’s $Q4 earnings are confirmed for after-market on February 28, 2022.
There is no upcoming split for Novavax.
Novavax is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.